Piers Ingram, founder and CEO of Singapore-based Hummingbird Bioscience and its U.S. spin-off Callio Therapeutics, is quietly ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

today announced positive 1-year event free survival (EFS), overall survival and safety clinical trial data updates from the 40 patient treatment arm of its Phase 2b clinical trial of immunotherapy ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

OS Therapies Inc (NYSE-A:OSTX) shares jumped 12.4% following favorable feedback from the FDA regarding its OST-HER2 treatment ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.